Search

Displaying results 4751 - 4760 of 5895 in total
  1. Drug

    MK-2748

    go.drugbank.com/drugs/DB15371
    Investigational

    MK-2748 is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)).

  2. Drug

    OBI-3424

    go.drugbank.com/drugs/DB16057
    Investigational

    OBI-3424 is under investigation in clinical trial NCT04315324 (Study to Test Akr1c3-activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/refractory T-cell Acute Lymphoblastic Leukemia (T-ALL

  3. Drug

    Galegenimab

    go.drugbank.com/drugs/DB18860
    Investigational

    Galegenimab is under investigation in clinical trial NCT03972709 (A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to

  4. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    burden compared to older agents such as [DB08873], [DB05521], [DB00008], [DB00022], and [DB00811]. … Paritaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

  5. Drug

    SGN-15

    go.drugbank.com/drugs/DB05818
    Investigational

    Monoclonal antibodies are substances that are made in the laboratory and that can locate and bind to cancer cells. Doxorubicin is a type of anthracycline antitumor antibiotic.

  6. Drug

    OPC-28326

    go.drugbank.com/drugs/DB05461
    Experimental

    At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary

  7. Drug

    ONT-093

    go.drugbank.com/drugs/DB14069
    Experimental

    In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics.

  8. Drug

    ONO-2952

    go.drugbank.com/drugs/DB14802
    Investigational

    ONO-2952 is under investigation in clinical trial NCT01887002 (Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable

  9. Drug

    IMCY-0141

    go.drugbank.com/drugs/DB17019
    Investigational

    IMCY-0141 is a synthetic peptide based on MOG (Myelin Oligodendrocyte Glycoprotein), a dominant autoantigen, designed to stop the progression of multiple sclerosis (MS) and the destruction of the myelin

  10. Drug

    Fianlimab

    go.drugbank.com/drugs/DB18858
    Investigational

    Fianlimab is under investigation in clinical trial NCT06190951 (A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-pd1 Alone in Adult Participants With Resectable Stage 3 or